Vanguard Global Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$116K Buy
26,851
+316
+1% +$1.85K ﹤0.01% 2703
2026
Q2
$213K Hold
26,535
– – ﹤0.01% 2476
2026
Q1
$213K Buy
+26,535
New +$254K ﹤0.01% 2419

Other funds holding SPRY

Vanguard Global Advisers's SPRY Position: Q3 2026 in Review

Vanguard Global Advisers increased its ARS Pharmaceuticals (SPRY) stake by 1.2% in Q3 2026, buying an estimated $1.85K and bringing the position to 26,851 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2703.

Vanguard Global Advisers first reported a position in SPRY in Q1 2026 and has held it in 3 quarters since. The position peaked at $213K in Q1 2026. 190 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Vanguard Global Advisers held 26,851 shares of ARS Pharmaceuticals worth $116K as of Q3 2026.
  • Vanguard Global Advisers bought 316 ARS Pharmaceuticals shares in Q3 2026, an estimated $1.85K.
  • ARS Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2703 holding.
  • Vanguard Global Advisers first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's ARS Pharmaceuticals position peaked at $213K in Q1 2026.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.